Key result
Pleconaril reduced the median time to headache resolution from 9.5 to 7.0 days compared to placebo in patients with concomitant moderate to severe nausea (P=0.009).
Why the study?
Does pleconaril reduce time to headache resolution in patients with enteroviral meningitis?
Population
607 randomized patients (240 confirmed to have enterovirus infection)
Comparison
Pleconaril 200 mg three times daily vs Identical-appearing placebo
Design
RCT, randomized, double-blind
Authors
Loading...
May support targeted pleconaril use in nauseated patients; confirms RCT subgroup benefit for enteroviral meningitis.
RCT (n=607)
Double-blind
randomized
Yes
Does pleconaril reduce time to headache resolution in patients with enteroviral meningitis?
Absolute Event Rate: 7% vs 9.5%
p-value: p=0.009
Pleconaril modestly shortens the duration of headache in patients with enteroviral meningitis, particularly in those with more severe baseline symptoms.
Desmond et al. (2006) conducted an RCT in Enteroviral meningitis (n=607). Pleconaril vs. identical-appearing placebo was evaluated on Time to headache resolution in patients with concomitant moderate to severe nausea at baseline (p=0.009). Pleconaril reduced the median time to headache resolution from 9.5 to 7.0 days compared to placebo in patients with concomitant moderate to severe nausea (P=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: